Stuart W. Peltz, Ph.D. | Chief Executive Officer
Stuart W. Peltz, Ph.D. founded PTC Therapeutics, Inc. in 1998 and has served as Chief Executive Officer and a member of the board of directors since the company's inception. Under his leadership, PTC has grown from a research organization based in the expertise of RNA processes and control to a publicly traded company on NASDAQ focused on the discovery, development and commercialization of orally-administered, small-molecule treatments for rare disorders and oncology.
Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. He and his team have shown the important interplay between the different RNA biology events that ultimately control protein production in the cell. He was involved in developing the first biochemical and genetic assays investigating the regulation of mRNA turnover subsequently demonstrating the strong connection between the processes of protein production and mRNA turnover. His work was instrumental in identifying and characterizing components of multiple mRNA decay and translation pathways. These findings have been translated to build novel drug discovery platforms and targets that allow PTC to search for potential new drugs to treat genetic disorders, oncology, and infectious diseases. Dr. Peltz’s development of the nonsense readthrough platform led to the discovery of the first approved drug for Duchenne muscular dystrophy in the European Union.
Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz has received a number of business and scientific awards. Notably, he was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He received the 2014 Dr. Sol J. Barer Award for Vision Innovation and Leadership and was recognized as PharmaVoice’s 100 Most Inspiring People in 2009. He is a member of the board of directors for the Biotechnology Industry Organization (BIO) and serves on BIO’s Emerging Companies Section Governing Board. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.
Neil Almstead, Ph.D. | Executive Vice President, Research, Pharmaceutical Operations & Technology
In his role as Executive Vice President, Neil Almstead, Ph.D. is responsible for all the discovery research to fuel PTC’s robust pipeline. He is also responsible for global manufacturing operations and supply chain of PTC’s lead product, Translarna. Dr. Almstead joined PTC in 2000 and has served in several executive positions, including, Senior Vice President, Research and CMC and VP of Chemistry and CMC. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders, oncology and inflammatory diseases. Dr. Almstead received a B.S. from Clarkson University and a Ph.D. in Organic Chemistry from the University of Illinois at Urbana-Champaign.
Mark E. Boulding | Executive Vice President and Chief Legal Officer
Mark Boulding has served as PTC's Executive Vice President and Chief Legal Officer since March 2012, and previously served as Senior Vice President and General Counsel from April 2002 to February 2012. Prior to joining the company, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two Washington, D.C.-based law firms. Mr. Boulding received a J.D. from the University of Michigan and a B.A. from Yale College.
Shane Kovacs | Executive Vice President, Chief Financial Officer and Head of Corporate Development
Mr. Kovacs joined PTC in June 2013. Prior to joining PTC, Mr. Kovacs served as Managing Director, Health Care Investment Banking at Credit Suisse. In this capacity, he focused on advising life sciences companies on transactions ranging from equity and debt financings to mergers and acquisitions. He joined Credit Suisse in 2004 and held various positions of increasing responsibility. Prior to Credit Suisse, Mr. Kovacs worked in investment banking at National Bank Financial in Toronto. Mr. Kovacs received an MBA from Richard Ivey School of Business at the University of Western Ontario and a Bachelors of Engineering in Chemical Engineering and a Bachelors of Sciences in Life Sciences from Queen's University in Kingston, Ontario. Mr. Kovacs is also a CFA Charterholder.
Tuyen Ong, M.D. | Chief Medical Officer
Tuyen Ong has served as Chief Medical Officer since April 2016. He joined PTC in September 2014 as Senior Vice President of Clinical Development and Translational Research where he built a high performing clinical department responsible for advancing PTCs pipeline. Prior to joining PTC, Dr. Ong served as Vice President of Global Clinical Development and Operations at Bausch and Lomb (subsequently Valeant Pharmaceuticals) and played a key role in Bausch and Lomb’s filing of new drug applications and its transformation into a global competitor in the specialty care sector. Previously, Dr. Ong worked at Pfizer Inc. in several therapeutic disease areas of high unmet need, including respiratory, gastrointestinal, hepatology and ophthalmology. Dr. Ong holds a medical degree from the University of London and received his MBA from New York University Stern School of Business.
Martin Rexroad | Senior Vice President, Human Resources
Martin Rexroad joined PTC in September 2013 as Senior Vice President of Human Resources. Mr. Rexroad has over 25 years of experience across all areas of Human Resources in multiple industries and stages of development. Prior to PTC, Martin served as Vice President of Human Resources at Terumo Medical Corporation. From April 2007 to April 2010, he served as Vice President of Human Resources at Osteotech, Inc. Prior to Osteotech, Mr. Rexroad held various positions in other industries including: New York Life Insurance Company and Altria Corporate Services, Inc. Mr. Rexroad received an M.S. in Business Administration focusing on Human Resources and Labor Relations and a B.S. in Business Management from Virginia Tech.
Mark Rothera | Chief Commercial Officer
Mark Rothera has served as Chief Commercial Officer since April 2013. Prior to joining PTC, Mr. Rothera served as Global President of Aegerion Pharmaceuticals Inc., a biopharmaceutical company, from April 2012 to January 2013. From January 2006 to March 2012, he served as Vice President and General Manager for the commercial operations of Shire Human Genetic Therapies in Europe, the Middle East & Africa. Prior to joining Shire, Mr. Rothera held various global strategic and operational marketing and sales roles with French and UK operations of Glaxo Wellcome. Mr. Rothera received an M.A. in Natural Science from Cambridge University and an M.B.A. from the European Institute for Business Administration.